AVH — AVITA Medical Share Price
Last trade - 00:00- AU$388.26m
- AU$398.22m
- $64.25m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 55.08 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.86 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -95.03% | ||
| Return on Equity | -230.96% | ||
| Operating Margin | -88.08% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 14.26 | 29.23 | 34.42 | 50.14 | 64.25 | 101.83 | 136.14 | 45.69% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
AVITA Medical, Inc. is a therapeutic acute wound care company. The Company’s technologies optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of its platform is the RECELL System for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin Cells, offering a solution for improved clinical outcomes at the point-of-care. In the United States, it also holds the exclusive rights to market, sell, and distribute Cohealyx, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix. Its technologies are designed to optimize skin restoration procedures, effectively accelerating patient healing and recovery. Its solutions improve the healing outcomes for patients with traumatic injuries and surgical repairs, addressing critical healing needs that arise from unpredictable and life-changing events.
Directors
- Lou Panaccio NEC (64)
- Michael Perry CEO (61)
- Michael Holder CFO (59)
- Kathy McGee COO (56)
- Andrew Quick CTO (50)
- Donna Shiroma GCN (58)
- Erin Liberto OTH (47)
- Jeremy Cook NID (71)
- James Corbett NID (63)
- Suzanne Crowe NID (69)
- Louis Drapeau NID (77)
- Jan Reed NID (61)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 17th, 2020
- Public Since
- March 18th, 2012
- No. of Shareholders
- 19,321
- No. of Employees
- 260
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 26,434,658
- Address
- 28159 Avenue Stanford, Suite 220, VALENCIA, 91355
- Web
- https://www.avitamedical.com/
- Phone
- +1 6613679170
- Contact
- Jessica Ekeberg
- Auditors
- Grant Thornton LLP
Upcoming Events for AVH
Similar to AVH
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
As of Today at 01:27 UTC, shares in AVITA Medical are trading at AU$2.98. This share price information is delayed by 15 minutes.
Shares in AVITA Medical last closed at AU$2.98 and the price had moved by +9.16% over the past 365 days. In terms of relative price strength the AVITA Medical share price has outperformed the ASX All Ordinaries Index by +1.32% over the past year.
The overall consensus recommendation for AVITA Medical is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreAVITA Medical does not currently pay a dividend.
AVITA Medical does not currently pay a dividend.
AVITA Medical does not currently pay a dividend.
To buy shares in AVITA Medical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$2.98, shares in AVITA Medical had a market capitalisation of AU$388.26m.
Here are the trading details for AVITA Medical:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: AVH
Based on an overall assessment of its quality, value and momentum AVITA Medical is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in AVITA Medical is AU$3.99. That is 34.06% above the last closing price of AU$2.98.
Analysts covering AVITA Medical currently have a consensus Earnings Per Share (EPS) forecast of -$0.44 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like AVITA Medical. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -2.04%.
As of the last closing price of AU$2.98, shares in AVITA Medical were trading -4.43% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The AVITA Medical PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$2.98.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
AVITA Medical's management team is headed by:
- Lou Panaccio - NEC
- Michael Perry - CEO
- Michael Holder - CFO
- Kathy McGee - COO
- Andrew Quick - CTO
- Donna Shiroma - GCN
- Erin Liberto - OTH
- Jeremy Cook - NID
- James Corbett - NID
- Suzanne Crowe - NID
- Louis Drapeau - NID
- Jan Reed - NID